Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trialAlessandro Gronchi, Paolo G. Casali, Stefano Ferrari et al.|The Lancet Oncology|2017Cited by 493
Combined vemurafenib and fotemustine in patients with BRAF V600 melanoma progressing on vemurafenibPaola Queirolo, Paolo A. Ascierto, Enrica T. Tanda et al.|Oncotarget|2016Cited by 12